• Alias: HuMax-CD20
    • A fully human, high-affinity IgG1 monoclonal antibody directed against the B-cell CD20 cell surface antigen
    • FDA approved for the treatment of CLL refractory to fludarabine and alemtuzumab
    • Currently in clinical trials for other hematologic malignancies
    • Recommended dose: 300 mg IV initial dose, followed 1 week later by 2,000 mg weekly for 7 doses, followed 4 weeks later by 2,000 mg every 4 weeks for 4 doses for total of 12 doses
    • Half-life: 4 days (between dose 4 and 12)
    • Common side effects: US box warning: Hepatitis B virus reactivation, eutropenia/anemia, diarrhea, infection, infusion-related reactions (50% in first dose)
    Other topics in Targeted and Immunotherapy Agents